Exchange: NASDAQ·Updated 07:58 PM EDT
HELP logo

HELPHelus Pharma Inc.

$6.48
$0.46
(7.64%)
Today
Closed $6.48
$0.01
(0.15%)
After Hours
EarningsJun 30
Mkt Cap$301.22M
Vol2.92M
News
all
press releases
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year PR Newswire NEW YORK and TORONTO, June 26, 2026 Issued on behalf of Helus PharmaHelus Pharma...
PR Newswire
News Placeholder
More News
News Placeholder
FNM News Break: Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
– APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder (“MDD”) is progressing as planned and has surpassed 86% enrollment – – Phase 2 HLP003 data demonstrated long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale (“MADRS”) score compared to baseline at 12 months after two 16 mg […] The post FNM News Break: Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress appeared first on Financial News Media.
Financial News Media
News Placeholder
Cybin (NASDAQ:HELP) Shares Up 2.7% - Should You Buy?
Cybin (NASDAQ:HELP) Shares Up 2.7% - Should You Buy...
MarketBeat
News Placeholder
FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain
The FDA stated that this will increase support for psychedelic-based medicines for the treatment of conditions like post-traumatic stress disorder, treatment-resistant depression, and major depressive disorder.
Stocktwits
News Placeholder
Cybin Inc. (NASDAQ:HELP) Given Average Recommendation of "Buy" by Brokerages
Shares of Cybin Inc. (NASDAQ:HELP - Get Free Report) have been assigned an average recommendation of "Buy" from the six analysts that are covering the firm, Marketbeat Ratings reports. Five analysts...
MarketBeat
News Placeholder
Cybin (NASDAQ:HELP) Now Covered by TD Cowen
TD Cowen assumed coverage on shares of Cybin in a research report on Monday. They set a "buy" rating and a $8.00 price objective on the stock...
MarketBeat
News Placeholder
Cybin (NASDAQ:HELP) Shares Down 2.1% - Time to Sell?
Cybin (NASDAQ:HELP) Trading Down 2.1% - Here's What Happened...
MarketBeat
News Placeholder
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions PR Newswire VANCOUVER, BC, March 9, 2026 Issued...
PR Newswire
News Placeholder
HELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upside
Jefferies highlighted the Phase 3 Approach trial for depression drug HLP003 as the next key catalyst for the stock.
Stocktwits
News Placeholder
Dow Futures Hold Ground After 800-Point Selloff As Oil Surge Hits Wall Street: Why MRVL, USO, COST, HELP Are Trending After-Hours
U.S. crude surged above $80 per barrel after a reported Iranian missile strike on an oil tanker.
Stocktwits
<
1
2
...
>

Advertisement|Remove ads.